Rockefeller University Press

Table II

Significantly expanded TCR Vβ–expressing cells after HSCT

Patient	T subset	TCR	Pre-Tx^{^a}	6 mo  after Tx	1 yr  after Tx	2 yr  after Tx
1	CD4⁺	BV1	2.5	8.8^{^b}	ND	3.5
	CD4⁺	BV17	10.5	32.0	ND	9.3
2	CD8⁺	BV18	0.5	6.1	2.2	2.0
	CD8⁺	BV20	2.6	7.6	8.1	9.4
4	CD8⁺	BV1	5.7	4.2	15.6	9.8
5	CD8⁺	BV8	6.9	17.9	14.0	18.9
	CD8⁺	BV21.3	1.4	3.6	2.9	6.6
6	CD8⁺	BV1	5.2	ND	17.5	9.9
	CD8⁺	BV5.1	3.5	ND	8.6	9.4
7	CD8⁺	BV5.1	1.75	6.8	4.7	ND
	CD8⁺	BV23	0.3	49.9	53.9	ND

Patient	T subset	TCR	Pre-Tx^{^a}	6 mo  after Tx	1 yr  after Tx	2 yr  after Tx
1	CD4⁺	BV1	2.5	8.8^{^b}	ND	3.5
	CD4⁺	BV17	10.5	32.0	ND	9.3
2	CD8⁺	BV18	0.5	6.1	2.2	2.0
	CD8⁺	BV20	2.6	7.6	8.1	9.4
4	CD8⁺	BV1	5.7	4.2	15.6	9.8
5	CD8⁺	BV8	6.9	17.9	14.0	18.9
	CD8⁺	BV21.3	1.4	3.6	2.9	6.6
6	CD8⁺	BV1	5.2	ND	17.5	9.9
	CD8⁺	BV5.1	3.5	ND	8.6	9.4
7	CD8⁺	BV5.1	1.75	6.8	4.7	ND
	CD8⁺	BV23	0.3	49.9	53.9	ND

^a

Tx, treatment.

^b

Bold numbers indicate a significant expansion according to the criteria described in Materials and methods.